Allogenic Hepatocyte Transplantation Into Periduodenal Lymph Nodes

PHASE2RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 11, 2022

Primary Completion Date

August 20, 2027

Study Completion Date

December 30, 2027

Conditions
End Stage Liver Disease
Interventions
BIOLOGICAL

LYG-LIV0001

Allogenic hepatocytes suspended in a buffered cell preservation solution with increasing number of lymph nodes being transplanted for the dose escalation. Subjects will also receive immune suppression, including tacrolimus capsules to follow the dose prescribed by the investigator as well as a short course of prednisone.

Trial Locations (2)

77030

RECRUITING

Houston Methodist Hospital, Houston

02111

WITHDRAWN

Tufts Medical Center, Boston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

LyGenesis, Inc.

INDUSTRY